RecruitingNot applicableNCT07187440
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- No intervention(other)
- Enrollment
- 200 enrolled
- Eligibility
- 7 years · All sexes
- Timeline
- 2025 – 2028
Study locations (18)
- The First Affiliated Hospital Of USTC (AnHui Provincial Hospital), Hefei, Anhui, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Fuzhou University Provincial Affiliated Hospital, Fuzhou, Fujian, China
- The Second Affiliated Hospital ZheJiang University School Of Medicine, Hangzhou, Guangdong, China
- ShanTou Central Hospital, Shantou, Guangdong, China
- The University Of Hong Kong-ShenZhen Hospital, Shenzhen, Guangdong, China
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
- Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
- The First Affiliated Hospital With NanJing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China
- The First Affiliated Hospital Of Soochow University, Suzhou, Jiangsu, China
- The Second Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi, China
- The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi, China
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07187440 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGPHASE2, PHASE3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A.
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.
- RECRUITINGPHASE1NCT06858397A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry DiseaseGC Biopharma Corp